On the 31st, Merck Korea announced that its Tepmetko (ingredient name: tepotinib), a treatment for MET-ex14 deletion-mutated non-small cell lung cancer, will be reimbursed as of the 1st of next month.

Accordingly, Tepmetko is now covered by reimbursement for patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 deletion, regardless of the treatment line (first or later line).

As a result, patients with MET exon 14 deletions may now use Tepmetko as a first-line treatment and receive reimbursement.

MET mutations, which occur in 1.8-3.1% of NSCLC patients in Korea, are very rare. They cause resistance to other anticancer treatments and hav